focus -WSS

focus

author：focus 2025-09-06 04:30:25 - browse：135

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Cheap, fast test for Zika and dengue could cost just $1

entertainment

WSS

Medical device trials still don't enroll enough women, study finds

Readers discuss the intersection of pregnancy and addiction

A new drug could help frostbite victims avoid its ravages

Cheap, fast test for Zika and dengue could cost just $1

California wildfire smoke linked to 52,000 early deaths, study says

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Wikipedia

focus

leisure time

Alkermes shareholders re

New CMS data security rules will hurt Medicare, Medicaid research

Continuity nursing helped my family in our darkest PICU moments

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Sports medicine is finally prioritizing gender equality

My daughter's legacy lives on through her writing, phage therapy

After affirmative action ruling, medical educators look to 'holistic review'

Hospitals are piloting generative AI tools as regulators play catch

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

A new drug could help frostbite victims avoid its ravages

leisure time

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Measles policy set amid Florida outbreak alarms vaccine proponents

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Obamacare plans could cover weight loss drugs

knowledge

focus

entertainment

leisure time